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COSTS AND CHARACTERISTICS OF PATIENTS
WHO UNDERGO BONE MARROW
TRANSPLANT (BMT)
Friedman JY1, Reed SD1, Glendenning A2, Schulman KA1
1Duke Clinical Research Institute, Durham, NC, USA;
2Novartis Pharmaceuticals, East Hanover, NJ, USA
OBJECTIVES: BMT is an important technology used 
in the treatment of cancer patients. Cost estimates for 
this procedure vary, and mostly derive from estimates
developed early in the dissemination of the technology.
Our objective was to describe the costs associated with
BMT.
METHODS: Using 1999 MarketScan data, we analyzed
commercial non-Medicare inpatient claims for patients
who underwent initial BMT. Costs are comprised of total
gross payments to all providers associated with the 
admission, including physicians and hospital facilities.
RESULTS: 69 patients were eligible for analysis. 42%
and 29% of the sample were from the North Central or
Southern region of the U.S. Mean age was 44 years. The
mean and median total claims paid for BMT were
$83,027 and $76,826, respectively (95% CI: $72,520,
$93,534). The average length of stay (LOS) was 25.6 
days (95% CI: 22.9, 28.4). Average costs increased as 
LOS increased ($49,501 for LOS 0–15, $74,384 for LOS
16–30, $99,050 for LOS 31–45, and $169,431 for LOS
> 45). The most frequent diagnoses for the sample were:
multiple myeloma 19%, non-Hodgkin’s lymphoma 16%,
other types of cancer 13%, myeloma 10%, and chronic
myeloid leukemia 9%. The average cost of BMT was 
signiﬁcantly more expensive for patients with a diagnosis
of leukemia (e.g. chronic myeloid leukemia) ($94,473)
versus patients with other types of cancer ($72,535) (95%
CI for the difference: $1,639, $42,498). Mean costs were
higher for patients who died ($111,025) versus those
patients discharged to their home, either under self-care
($80,618) or medical supervision ($65,291).
CONCLUSIONS: We found that costs for BMT vary by
diagnosis, LOS, and patient outcomes. Our estimate for
BMT appears to be less expensive than initial estimates
($250,000). However, our analysis only included costs 
for initial BMT whereas other cost estimates include 
additional costs, such as costs for rehospitalizations,
follow-up care and outpatient medications.
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AN UPDATED RISK THRESHOLD MODEL FOR 
G-CSF PROPHYLAXIS USE IN CANCER
CHEMOTHERAPY: INCORPORATION OF
PATIENT OUT-OF-POCKET AND INDIRECT
COSTS
Cosler LE1,Agboola O2, Calhoun EA3, Lyman GH2
1Albany College of Pharmacy, Albany, NY, USA; 2Albany
Medical Center, Albany, NY, USA; 3Northwestern University
Medical School, Chicago, IL, USA
Prophylactic granulocyte-colony stimulating factor 
(G-CSF) reduces the incidence and duration of
chemotherapy-induced neutropenia (CIN), thereby reduc-
ing the risk of complications, dose delays, and reductions
that may compromise outcomes. A published risk thresh-
old model for the cost-effective use of prophylactic G-CSF
used direct costs derived from randomized clinical trials.
With direct cost estimates of $1,000 per day, prophylac-
tic G-CSF becomes cost-effective when the risk of hospi-
talization exceeds 40%, and this value is reﬂected in
current ASCO guidelines for CSF use (Lyman et al, JNCI,
1993). An updated analysis incorporating total institu-
tional costs of $1750 per day reduces the risk threshold
to 23% (Lyman et al, Eur J Cancer, 1998).
OBJECTIVE: Utilizing indirect cost estimates for neu-
tropenia obtained from a pilot study (Calhoun at al, The
Oncologist, 2001), the risk threshold model was modiﬁed
to incorporate indirect costs.
METHODS: For parameters describing patients not
receiving G-CSF, the indirect costs were fully added to 
the direct institutional costs. For the parameters describ-
ing patients receiving prophylactic G-CSF, the indirect
costs were adjusted by the reduced incidence of severe
neutropenia (50%), and further by the reduced probabil-
ity of the development of febrile neutropenia (50%)
related to G-CSF use. The new model was evaluated for
indirect cost estimates ranging from $1,000 through
$5,000 per episode. Patient out-of-pocket and indirect
costs for an episode of severe neutropenia were estimated
at $5,176 per episode, excluding hospitalizations
(Calhoun at al, The Oncologist, 2001).
RESULTS: The addition of indirect costs yields a reduced
threshold for prophylactic G-CSF use from 23% (no 
indirect costs) to 8% ($5,000 indirect costs).
CONCLUSION: The incorporation of indirect costs into
economic models provides a more complete assessment 
of the impact of prophylactic G-CSF from a societal 
perspective. Additional study of the model assumptions
and indirect cost estimates are needed to further improve
the decision model.
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COST-EFFECTIVENESS OF RITUXIMAB IN
DIFFUSE LARGE B CELL LYMPHOMA
Best JH1, Hornberger J2, Omnes LF3, Coifﬁer B4
1Acumen, LLC, Burlingame, CA, USA; 2Acumen, LLC and
Stanford University School of Medicine, Burlingame, CA, USA;
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OBJECTIVES: Rituximab (MabThera) combined with
CHOP chemotherapy (R-CHOP) signiﬁcantly prolongs
event-free and overall survival of patients with diffuse
large B-cell lymphoma (DLCL) (GELA LNH 98–5 Study).
We estimated the cost-effectiveness of R-CHOP.
METHODS: The analyses were based on a randomized-
controlled trial comparing R-CHOP with CHOP, from a
French health system perspective. Patients (n = 399) were
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eligible if age 60–80 years, had stage II-IV DLCL, and
had ECOG performance status of 0–2. Mean patient 
survival in each treatment arm and chemotherapy costs
during treatment (q3 weeks ¥ 8 cycles) were estimated
from trial data. The longest duration of follow-up was 34
months. We estimated survival and cost-effectiveness up
to a time horizon of 10 years. Survival for each IPI strata
was estimated using the Kaplan-Meier method; survival
after the longest observed time in the trial was estimated
using published mortality rates (Shipp, NEJM, 93).
French DRG payments were applied to trial data on 
hospital use and treatments for adverse events. French
drug prices and drug administration costs were used to
estimate the costs of R-CHOP and CHOP regimens.
Costs and survival were discounted at 3.0%. R-CHOP
increased survival from 56% to 63% at the time of last
follow-up (34 months).
RESULTS: The mean duration of survival was 820 days
for R-CHOP and 721 days for CHOP, resulting in a mean
increase in survival of 0.27 years. Extrapolating to 10
years, R-CHOP is projected to increase discounted mean
survival by 0.54 years. Therapy-related cost during the
trial period was 15,000 euros higher with R-CHOP, with
a cost per life-year gained (LYG) of 55,300 euros. Over
10 years, total added cost per patient was 15,270 euros
and the estimated cost per LYG was 28,410 euros.
CONCLUSIONS: R-CHOP increases chance of cure
compared with CHOP and is cost-effective compared
with other treatments in widespread use.
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GENDER, FAMILY HISTORY AND OPTIMAL
LIFETIME SCREENING PROGRAMS FOR
COLORECTAL CANCER:A MODEL BASED
ECONOMIC EVALUATION
Sahmoun A, Balkrishnan R
Wake Forest University School of Medicine, Winston-Salem,
NC, USA
OBJECTIVE: Our aim is to describe a model that can be
used to calculate the costs and life-years gained from any
given screening program, and for any particular combi-
nation of risk factors for colorectal cancer (CRC). A trial
cannot evaluate more than a handful of these programs,
which suggests there may be a role for mathematical 
modeling techniques in identifying the designs worth 
evaluating in an interventional study.
METHODS: We used a Markov process model with time-
dependent transition probabilities to generate data on the
cost-effectiveness of various lifetime screening programs.
Our model represents the evolution of colorectal cancer
by ﬁve states; polyp-free colon, colon with benign
tumor(s), asymptomatic carcinomic colon, symptomatic
colonic cancer and death. We considered that progression
is related to prognosis via the Duke’s classiﬁcation system.
We have chosen a cycle length of one year for our model.
The outcome measure used is life expectancy from birth.
RESULTS: Our results suggest that with frequent 
screening the detrimental effects of genetic risk on life
expectancy can be almost completely countered. Screen-
ing can actually be cheaper than not screening, when costs
of treatment are included, especially for high-risk indi-
viduals. Hemoccult followed by colonoscopy if positive
is much cheaper than colonoscopy alone and, if carried
out frequently, almost as effective. Altering the age of ﬁrst
screening has a much less important effect on costs and
beneﬁts than altering the frequency. In order to counter
the effect of genetic risk on mortality, screening has to
begin much earlier for men than women.
CONCLUSIONS: Hemoccult followed by colonoscopy if
positive is a favorable strategy, even for high-risk groups,
but that the optimal frequency of screening is likely to
depend on gender and genetic susceptibility. These results
may be useful in designing future CRC screening trials.
PCN15
CLINICAL AND ECONOMIC OUTCOMES
ASSOCIATED WITH METASTATIC COLORECTAL
CANCER IN MANAGED CARE POPULATIONS:
CAPECITABINE (XELODA®) VERSUS
COMPARISON THERAPIES
Baran RW1, Dupere WM2,Taylor K2, Miao S3, Joseph J3,
Ilersich L4, Pandey L3
1Roche Laboratories, Inc, Nutley, NJ, USA; 2Lifemetrix, McLean,
VA, USA; 3University of the Sciences in Philadelphia,
Philadelphia, PA, USA; 4Hoffman La Roche Ltd, Mississauga,
ON, Canada
OBJECTIVE: To examine and compare treatment 
outcomes and economic beneﬁts in metastatic colorectal
cancer with an oral ﬂuoropyrimidine, capecitabine, versus
comparison therapies.
METHODS: A retrospective, matched-cohort study
design was used to abstract medical and retail pharmacy
claims records of 271 metastatic colorectal cancer
patients from a managed care, disease management 
database over a 30-month period. Patients were matched
in two study cohorts based on their treatment,
capecitabine (n = 78) vs. 5FULV +/- irinotecan (CPT) (n
= 193). The 5FU comparison cohort was comprised of
three therapy sub-groups: 5FULV (n = 78), 5FULV then
CPT (n = 78), and 5FULV plus CPT (n = 37). Time to
treatment discontinuation and survival were compared
between cohorts. The total direct cost of cancer care 
was captured through reimbursement claims. Cost-
effectiveness (cost per treatment duration) was calculated
for both cohorts.
RESULTS: Patients were well matched by age, gender,
metastases and co-morbidity status. Time to treatment
discontinuation with capecitabine was not signiﬁcantly
different than the comparison cohort (79 days vs. 104
days). Median estimated survival for capecitabine was
favorable relative to the comparison cohort (599 days 
vs. 530 days, p = 0.05). The total direct cost of cancer
care per patient was lower for capecitabine ($6,007 vs.
$13,339). Consequently cost-effectiveness ratio per
patient was lower for capecitabine than for the com-
